Shanghai Escugen Biotechnology Co., Ltd

This study tested an experimental drug called ESG401 in 156 people with advanced solid tumors (including breast, lung, and colorectal cancers) who had no other treatment options. The goal was to check the drug's safety, find the right dose, and see if it could shrink tumors. The …

This early-phase trial tested a new drug called ESG206 in 13 adults with B-cell blood cancers that had not responded to standard treatments. ESG206 is an antibody designed to attach to a protein called BAFFR on cancer cells and help the immune system attack them. The main goals w…